3 registrations that name VK2735 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Trial FinderInvestigational, not FDA-approvedRead from ClinicalTrials.gov Oct 20, 2026The VK2735 peptide page
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT07838740
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
Phase 1
Viking Therapeutics, Inc.
About 270 people
Started Nov 18, 2025
In plain words A Phase 1 study of VK2735 in people 18 to 60, run by Viking Therapeutics, Inc.. It plans to enroll about 270 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Obese Adults.
Must be capable of giving a signed informed consent form (ICF).
Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study…
BMI ≥ 30 kg/m2.
Willing to comply with contraceptive requirements.
The exclusion criteria are on the listing.
What it tests, as registered
VK2735 Drug; Placebo
Registered summary
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
Where, as registered
2 US sites in 2 states.
Not yet recruitingNCT07868835
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
Phase 3
Viking Therapeutics, Inc.
About 560 people
Starts Nov 2026 (estimated)
In plain words A Phase 3 study of VK2735 in people 18 and older, run by Viking Therapeutics, Inc.. It plans to enroll about 560 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Weight Loss.
Age ≥18 years of age at the time of signing the informed consent.
Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).
Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
VK2735; Placebo comparator
Registered summary
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
Phase 3
Viking Therapeutics, Inc.
About 560 people
Starts Nov 2026 (estimated)
In plain words A Phase 3 study of VK2735 in people 18 and older, run by Viking Therapeutics, Inc.. It plans to enroll about 560 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Weight Loss.
Age ≥18 years of age at the time of signing the informed consent.
Body mass index (BMI) ≥ 27 kg/m2
Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with HbA1c ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening.
The exclusion criteria are on the listing.
What it tests, as registered
VK2735 Oral; Placebo Comparator
Registered summary
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.